Celltrion's Herzuma (trastuzumab- biosimilar) Receives ANVISA's Approval for Breast and Gastric Cancer in Brazil
Shots:
- The Brazilian Health Regulatory Agency- ANVISA (Agencia Nacional de Vigilancia Sanitaria) has approved Herzuma (trastuzumab) in 150mg & 440mg for early-stage breast cancer- metastatic breast cancer and metastatic gastric cancer on May 20- 2019
- Celltrion is also expecting ANVISA’s approval for Truxima- a biosimilar of Rituximab which helps in securing a leading market position in the Central-South American biosimilar market
- Herzuma (trastuzumab-pkrb) is a biosimilar of Herceptin and has received FDA’s approval in Dec’18- also approved in EU (marketed by Mundipharma)- in Japan (marketed by Daiichi Sankyo) and in Australia
Ref: Celltrion | Image: Celltrion
Click here to read the full press release
Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.
